Avalo Therapeutics (AVTX) CMO Doyle Mittie Exercises Options, Sells Shares

What Happened
Doyle Mittie, Chief Medical Officer of Avalo Therapeutics (AVTX), exercised 679 stock options on August 10, 2026 at an exercise price of $8.04 ($5,459 total) and sold those 679 shares in an open-market transaction the same day at $20.00 per share, generating proceeds of $13,580. The reporting form shows the option/derivative was surrendered in connection with the exercise.

Key Details

• Transaction date: August 10, 2026. Form 4 filed August 12, 2026 (timely filing).
• Exercise: 679 shares at $8.04 each — total exercise cost $5,459 (transaction code M).
• Sale: 679 shares at $20.00 each — total proceeds $13,580 (transaction code S).
• Derivative disposition: 679 option units reported as disposed at $0.00 (reflects cancellation of the option upon exercise).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Footnotes: (F1) Transactions were made under a Rule 10b5-1 trading plan adopted Nov 13, 2025. (F2) The option’s vesting schedule: 25% vested Jan 28, 2026, remainder vesting monthly over the next three years, subject to continued service.

Context
This was an exercise followed by an immediate sale (often called a cashless or same-day sell). The use of a pre-established 10b5-1 plan indicates the sale was executed according to a predetermined trading plan rather than ad-hoc market timing. The transactions are routine insider activity and factual in nature; they do not by themselves indicate the insider’s future view of the company.